OSE Immunotherapeutics - Full Lusvertikimab results reflect potential in UC
OSE Immunotherapeutics’ final analysis of the CoTikiS trial in ulcerative colitis (UC) confirmed that Lusvertikimab met the primary endpoint with...
247 Views
OSE Immunotherapeutics - Riding the H124 tailwinds
OSE Immunotherapeutics has reported its results for H124, a standout period for the company’s development pipeline, with the momentum carrying into...
189 Views
OSE Immunotherapeutics - Tedopi registrational study commences
OSE Immunotherapeutics has announced the initiation of its Phase III registrational study (Artemia) for lead cancer vaccine Tedopi, with the trial...
252 Views
OSE Immunotherapeutics - Lusvertikimab shines in Phase II UC trial
OSE Immunotherapeutics’ run of positive news continues with the announcement of encouraging data from the Phase II proof-of-concept CoTikiS study,...
318 Views
OSE Immunotherapeutics - Another partnership with expansion into CAR-T
OSE Immunotherapeutics has entered into a commercial and revenue sharing agreement with the Memorial Sloan Kettering Cancer Center (MSK), focused...
229 Views